Search research articles
Contact Us
Filters
Showing results (201-210 of 407) with videos related to
Page
of 41
Sort By:
Life Sciences
|
July 11, 1983
Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not that of alpha methyl-p-tyrosine
A Reches, M N Hassan, V R Jackson, et al.
Neurology
|
February 1, 1984
Pergolide therapy for Parkinson's disease: neurobehavioral changes
Y Stern, R Mayeux, J Ilson, et al.
Annals of Neurology
|
December 1, 1996
Selegiline and mortality in Parkinson's disease
C W Olanow, S Fahn, J W Langston, et al.
Advances in Neurology
|
January 1, 1979
Anoxic myoclonus in the rat
J N Sharma, S R Snider, S Fahn, et al.
The Laryngoscope
|
February 1, 1988
Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia)
A Blitzer, M F Brin, S Fahn, et al.
Life Sciences
|
March 15, 1977
Changes in adrenal dopamine concentration after metyrapone or ACTH administration: implications for the in vivo regulation of dopamine beta-hydroxylase by glucocorticoids
S R Snider, D Sahar, A L Prasad, et al.
Annals of Neurology
|
December 1, 1986
Correlates of early disability in Huntington's disease
R Mayeux, Y Stern, A Herman, et al.
Brain Research
|
November 18, 1985
Presynaptic inhibition of dopamine synthesis in rat striatum: effects of chronic dopamine depletion and receptor blockade
A Reches, H R Wagner, V Jackson-Lewis, et al.
Neurology
|
February 1, 1997
Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease
E D Louis, L A Klatka, Y Liu, et al.
Archives of Neurology
|
July 1, 1996
Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients
S L Pullman, P Greene, S Fahn, et al.
Page
of 41
Search research articles
Search
Showing results (201-210 of 407) with videos related to
Sort By:
Page
of 41
Life Sciences
|
July 11, 1983
Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not that of alpha methyl-p-tyrosine
A Reches, M N Hassan, V R Jackson, et al.
Neurology
|
February 1, 1984
Pergolide therapy for Parkinson's disease: neurobehavioral changes
Y Stern, R Mayeux, J Ilson, et al.
Annals of Neurology
|
December 1, 1996
Selegiline and mortality in Parkinson's disease
C W Olanow, S Fahn, J W Langston, et al.
Advances in Neurology
|
January 1, 1979
Anoxic myoclonus in the rat
J N Sharma, S R Snider, S Fahn, et al.
The Laryngoscope
|
February 1, 1988
Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia)
A Blitzer, M F Brin, S Fahn, et al.
Life Sciences
|
March 15, 1977
Changes in adrenal dopamine concentration after metyrapone or ACTH administration: implications for the in vivo regulation of dopamine beta-hydroxylase by glucocorticoids
S R Snider, D Sahar, A L Prasad, et al.
Annals of Neurology
|
December 1, 1986
Correlates of early disability in Huntington's disease
R Mayeux, Y Stern, A Herman, et al.
Brain Research
|
November 18, 1985
Presynaptic inhibition of dopamine synthesis in rat striatum: effects of chronic dopamine depletion and receptor blockade
A Reches, H R Wagner, V Jackson-Lewis, et al.
Neurology
|
February 1, 1997
Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease
E D Louis, L A Klatka, Y Liu, et al.
Archives of Neurology
|
July 1, 1996
Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients
S L Pullman, P Greene, S Fahn, et al.
Page
of 41